Staar Surgical Company (STAA)

$17.76 -0.12 (-0.67%)
Market Cap 883.42M
Revenue (ttm) 313.90M
Net Income (ttm) -20.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 596.00
Profit Margin -6.44%
Debt to Equity Ratio 0.00
Volume 699,200
Avg Vol 1,599,878
Day's Range N/A - N/A
Shares Out 49.74M
Stochastic %K 76%
Beta 1.06
Analysts Hold
Price Target $23.23

Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 626 303 7902
Fax: 626 359 8402
Address:
25510 Commercentre Drive, Lake Forest, United States
Bogwood
Bogwood Feb. 22 at 10:50 PM
$NPCE $STAA Glad to see Patrick got quickly back on his feet after last year's implosion. I always felt like he and Tom were dealt short hands of the stick, just unlucky timing. What a consequential beard, though! 😂
0 ¡ Reply
ZacksResearch
ZacksResearch Feb. 19 at 5:37 PM
$STAA just got a major green light — and the stock is responding 🚀 Shares jumped 8% after the FDA expanded the EVO ICL age range to 21–60, supported by strong safety data and rising demand for LASIK alternatives. That’s a meaningful market expansion with real momentum behind it. See what this approval could mean for the growth story 👉 https://www.zacks.com/stock/news/2872369/staa-gains-fda-nod-to-expand-evo-icl-age-indication-to-60-years?cid=sm-stocktwits-2-2872369-teaser-34313&ADID=SYND_STOCKTWITS_TWEET_2_2872369_TEASER_34313
0 ¡ Reply
ZacksResearch
ZacksResearch Feb. 19 at 4:37 PM
$STAA gains 8.4% following FDA's expanded approval for EVO ICL, broadening its age range to 21-60 📈 This taps into shifting patient preferences as LASIK demand declines by 40% in three years, positioning STAA for growth in vision correction solutions 👉 https://www.zacks.com/stock/news/2872369/staa-gains-fda-nod-to-expand-evo-icl-age-indication-to-60-years?cid=sm-stocktwits-2-2872369-body-34285&ADID=SYND_STOCKTWITS_TWEET_2_2872369_BODY_34285
0 ¡ Reply
StockBraker
StockBraker Feb. 19 at 3:27 PM
$STAA Great news
0 ¡ Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 2:19 AM
$STAA Current Stock Price: $17.57 Contracts to trade: $17.5 STAA Feb 20 2026 Call Entry: $0.35 Exit: $0.55 ROI: 57% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 ¡ Reply
scalperD
scalperD Feb. 18 at 3:00 PM
$STAA - FDA expansion for STAAs implants (45 yrs old to 60) could potentially add 8 million refractive patients to the market. This could possibly bring Alcon back in with higher bid , or pvt equity.
0 ¡ Reply
SuperGreenToday
SuperGreenToday Feb. 14 at 2:19 AM
$STAA Share Price: $16.10 Contract Selected: Sep 18, 2026 $20 Calls Buy Zone: $1.19 – $1.47 Target Zone: $2.02 – $2.47 Potential Upside: 60% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
Estimize
Estimize Feb. 12 at 9:00 PM
Wall St is expecting 0.04 EPS for $STAA Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/staa?chart=historical&metric_name=eps&utm_co
0 ¡ Reply
Wisenheimer
Wisenheimer Feb. 10 at 11:39 PM
$STAA problem w audited results ? Their over a month overdue due from announcing a date
0 ¡ Reply
StockBraker
StockBraker Feb. 10 at 9:21 PM
$STAA So no ER today. Maybe next Tuesday?
0 ¡ Reply
Latest News on STAA
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

Feb 17, 2026, 4:01 PM EST - 5 days ago

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

Feb 2, 2026, 7:00 AM EST - 21 days ago

STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence

Jan 15, 2026, 1:06 PM EST - 5 weeks ago

STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence

STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

Jan 15, 2026, 8:30 AM EST - 5 weeks ago

STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

Alcon Terminates Agreement to Acquire STAAR Surgical

Jan 6, 2026, 8:00 PM EST - 6 weeks ago

Alcon Terminates Agreement to Acquire STAAR Surgical

ALC

STAAR Surgical Merger With Alcon Fails After Shareholders Vote No

Jan 6, 2026, 1:10 PM EST - 6 weeks ago

STAAR Surgical Merger With Alcon Fails After Shareholders Vote No

ALC

Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon

Jan 6, 2026, 9:52 AM EST - 6 weeks ago

Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon

ALC

Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing

Jan 6, 2026, 9:46 AM EST - 6 weeks ago

Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing

ALC

STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders

Jan 6, 2026, 8:47 AM EST - 6 weeks ago

STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders

Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon

Dec 19, 2025, 12:59 PM EST - 2 months ago

Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon

ALC

Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders

Dec 19, 2025, 11:45 AM EST - 2 months ago

Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders

ALC

Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.

Dec 17, 2025, 4:53 PM EST - 2 months ago

Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.

ALC

Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails

Dec 17, 2025, 1:17 PM EST - 2 months ago

Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails

ALC

STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value

Dec 17, 2025, 10:55 AM EST - 2 months ago

STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value

ALC

Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory

Dec 16, 2025, 1:32 PM EST - 2 months ago

Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory

Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction

Dec 16, 2025, 9:12 AM EST - 2 months ago

Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction

ALC

Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

Dec 16, 2025, 7:00 AM EST - 2 months ago

Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon

ALC

Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger

Dec 15, 2025, 6:35 PM EST - 2 months ago

Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger

Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon

Dec 12, 2025, 8:40 AM EST - 2 months ago

Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon

ALC

STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process

Dec 11, 2025, 9:47 AM EST - 2 months ago

STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process

ALC

Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon

Dec 11, 2025, 7:00 AM EST - 2 months ago

Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon

ALC

STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process

Dec 10, 2025, 12:53 PM EST - 2 months ago

STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process

ALC

Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer

Dec 10, 2025, 7:05 AM EST - 2 months ago

Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer

ALC

Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical

Dec 9, 2025, 12:39 PM EST - 2 months ago

Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical

ALC

Alcon Announces Amended Merger Agreement with STAAR Surgical

Dec 9, 2025, 8:30 AM EST - 2 months ago

Alcon Announces Amended Merger Agreement with STAAR Surgical

ALC

Broadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop Process

Dec 8, 2025, 1:28 PM EST - 2 months ago

Broadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop Process

ALC

Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon

Dec 8, 2025, 8:16 AM EST - 2 months ago

Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon

ALC

STAAR Surgical Announces Expiration of Go-Shop Period

Dec 8, 2025, 8:00 AM EST - 2 months ago

STAAR Surgical Announces Expiration of Go-Shop Period

ALC

Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors

Dec 2, 2025, 4:14 PM EST - 2 months ago

Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors

Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

Nov 10, 2025, 8:00 AM EST - 3 months ago

Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

ALC

STAAR Surgical Announces Amendments to Alcon Merger Agreement

Nov 7, 2025, 10:10 AM EST - 3 months ago

STAAR Surgical Announces Amendments to Alcon Merger Agreement

ALC

Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated

Nov 6, 2025, 6:21 AM EST - 3 months ago

Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated

STAAR Surgical Reports Third Quarter 2025 Results

Nov 5, 2025, 4:01 PM EST - 3 months ago

STAAR Surgical Reports Third Quarter 2025 Results

Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects

Nov 4, 2025, 11:52 AM EST - 3 months ago

Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects

ALC

Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon

Oct 31, 2025, 12:00 PM EDT - 4 months ago

Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon

ALC

STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon

Oct 27, 2025, 8:00 AM EDT - 4 months ago

STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon

ALC

Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon

Oct 24, 2025, 6:03 PM EDT - 4 months ago

Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon

ALC

Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction

Oct 24, 2025, 8:00 AM EDT - 4 months ago

Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction

ALC

Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders

Oct 23, 2025, 12:09 PM EDT - 4 months ago

Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders

ALC

Staar Surgical's top investor calls shareholder meeting to remove directors

Oct 22, 2025, 7:44 AM EDT - 4 months ago

Staar Surgical's top investor calls shareholder meeting to remove directors

Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors

Oct 22, 2025, 6:17 AM EDT - 4 months ago

Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors

Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction

Oct 20, 2025, 5:32 PM EDT - 4 months ago

Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction

ALC

Broadwood Partners Highlights Growing Opposition to STAAR Surgical's Proposed Sale to Alcon

Oct 20, 2025, 8:42 AM EDT - 4 months ago

Broadwood Partners Highlights Growing Opposition to STAAR Surgical's Proposed Sale to Alcon

ALC

STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025

Oct 20, 2025, 7:30 AM EDT - 4 months ago

STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025

Broadwood Partners Issues Letter to STAAR Surgical's Board Urging it to Allow Timely Shareholder Vote on Alcon Sale

Oct 17, 2025, 8:00 AM EDT - 4 months ago

Broadwood Partners Issues Letter to STAAR Surgical's Board Urging it to Allow Timely Shareholder Vote on Alcon Sale

ALC

STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon

Oct 16, 2025, 4:15 PM EDT - 4 months ago

STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon

Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon

Oct 15, 2025, 1:36 PM EDT - 4 months ago

Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon

ALC

Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon

Oct 14, 2025, 2:29 PM EDT - 4 months ago

Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon

ALC

Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale

Oct 10, 2025, 1:11 PM EDT - 4 months ago

Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale

ALC

STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card

Oct 8, 2025, 11:40 AM EDT - 4 months ago

STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card

ALC

Bogwood
Bogwood Feb. 22 at 10:50 PM
$NPCE $STAA Glad to see Patrick got quickly back on his feet after last year's implosion. I always felt like he and Tom were dealt short hands of the stick, just unlucky timing. What a consequential beard, though! 😂
0 ¡ Reply
ZacksResearch
ZacksResearch Feb. 19 at 5:37 PM
$STAA just got a major green light — and the stock is responding 🚀 Shares jumped 8% after the FDA expanded the EVO ICL age range to 21–60, supported by strong safety data and rising demand for LASIK alternatives. That’s a meaningful market expansion with real momentum behind it. See what this approval could mean for the growth story 👉 https://www.zacks.com/stock/news/2872369/staa-gains-fda-nod-to-expand-evo-icl-age-indication-to-60-years?cid=sm-stocktwits-2-2872369-teaser-34313&ADID=SYND_STOCKTWITS_TWEET_2_2872369_TEASER_34313
0 ¡ Reply
ZacksResearch
ZacksResearch Feb. 19 at 4:37 PM
$STAA gains 8.4% following FDA's expanded approval for EVO ICL, broadening its age range to 21-60 📈 This taps into shifting patient preferences as LASIK demand declines by 40% in three years, positioning STAA for growth in vision correction solutions 👉 https://www.zacks.com/stock/news/2872369/staa-gains-fda-nod-to-expand-evo-icl-age-indication-to-60-years?cid=sm-stocktwits-2-2872369-body-34285&ADID=SYND_STOCKTWITS_TWEET_2_2872369_BODY_34285
0 ¡ Reply
StockBraker
StockBraker Feb. 19 at 3:27 PM
$STAA Great news
0 ¡ Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 2:19 AM
$STAA Current Stock Price: $17.57 Contracts to trade: $17.5 STAA Feb 20 2026 Call Entry: $0.35 Exit: $0.55 ROI: 57% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 ¡ Reply
scalperD
scalperD Feb. 18 at 3:00 PM
$STAA - FDA expansion for STAAs implants (45 yrs old to 60) could potentially add 8 million refractive patients to the market. This could possibly bring Alcon back in with higher bid , or pvt equity.
0 ¡ Reply
SuperGreenToday
SuperGreenToday Feb. 14 at 2:19 AM
$STAA Share Price: $16.10 Contract Selected: Sep 18, 2026 $20 Calls Buy Zone: $1.19 – $1.47 Target Zone: $2.02 – $2.47 Potential Upside: 60% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
Estimize
Estimize Feb. 12 at 9:00 PM
Wall St is expecting 0.04 EPS for $STAA Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/staa?chart=historical&metric_name=eps&utm_co
0 ¡ Reply
Wisenheimer
Wisenheimer Feb. 10 at 11:39 PM
$STAA problem w audited results ? Their over a month overdue due from announcing a date
0 ¡ Reply
StockBraker
StockBraker Feb. 10 at 9:21 PM
$STAA So no ER today. Maybe next Tuesday?
0 ¡ Reply
timetravelBob
timetravelBob Feb. 5 at 6:05 PM
$STAA just a litttle bit more then its a super strong buy
0 ¡ Reply
timetravelBob
timetravelBob Feb. 4 at 8:59 PM
$STAA as china's economy does so will staa
0 ¡ Reply
VolumeVista
VolumeVista Feb. 4 at 3:20 PM
$STAA is a medical device company focused on ophthalmic surgery; its growth is driven by technological innovation and surgeon adoption in a specialized field.
0 ¡ Reply
BioTuesdays
BioTuesdays Feb. 2 at 6:36 PM
$STAA has announced that its board of directors has appointed Warren Foust, president and CEO, and Deborah Andrews, CFO, as interim co-CEOs, effective yesterday https://biotuesdays.com/2026/02/02/staar-appoints-warren-foust-and-deborah-andrews-as-interim-co-ceos/
0 ¡ Reply
Bogwood
Bogwood Feb. 2 at 3:59 PM
$LCTX $STAA $IMDX anyone else surprised at how much light is behind Neal's eyes? Thought he would've had a jaded death stare after dealing with these companies for so long lol
2 ¡ Reply
Goblinvomit
Goblinvomit Jan. 30 at 8:42 PM
$STAA lol, glad I made out by selling then shorting this pig at $25.
1 ¡ Reply
StockBraker
StockBraker Jan. 29 at 3:50 PM
$STAA May take a while to get back above $30, but given that Broadwood wants more than what Alcon was offering ($30.75) they will do everything in their power to get the share price up - either through another deal or organic share price appreciation. I would have been willing to have taken the Alcon offer, but I don't hold the cards and it's Dealer's choice. Might as well take advantage of these low prices. If we do get above $32 that's a minimum 68% ROI.
1 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 29 at 5:17 AM
$STAA RSI: 21.10, MACD: -1.3325 Vol: 1.55, MA20: 21.39, MA50: 23.74 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
ffdseh
ffdseh Jan. 19 at 5:42 AM
$STAA Seems that one going on that we're going under the knife for eent and other surgeries and were also given pelvic exams, Without their knowlledge or concent. And had catheters inserted, to show interns and new medical staff. They never told rhe woman that this would be done to them. They may of went in for ent surgerymay have had any intention surgery.And while were having that, they were being taken advantage of by a line of gluved interns. Seems some states are beginning to STOP this procedure , while many others still do it. I believe this happened to my wife years ago in Boston. Cancel medical schools , training schools , training hospitals have been going out of the way to defend this practice for years. Is it just me or just a horrible , horrible , horrible practice
1 ¡ Reply
BaroloBuff
BaroloBuff Jan. 19 at 1:58 AM
$STAA Greed & incompetence management kills most companies this size. Get out while you can.
0 ¡ Reply
scalperD
scalperD Jan. 18 at 4:26 PM
$STAA -probably the best small cap special sit play I've come across in a while. Broadwood and Yunqi get paid on returns. Either Alcon comes back higher or there is another interested party - like the risk/reward
1 ¡ Reply
mbrandi
mbrandi Jan. 16 at 7:40 PM
$STAA Crazy price action today, I assume Broadwood will have swept up some more, but we'll see if the filings come through.
0 ¡ Reply